

7. Taniguchi Y, Nosaka K, Yasunaga J, Maeda M, Mueller N, Okayama A, Matsuoka M: Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. *Retrovirology* 2005, 2:64
8. Furukawa Y, Osame M, Kubota R, Tara M, Yoshida M: Human T-cell leukemia virus type-1 (HTLV-1) Tax is expressed at the same level in infected cells of HTLV-1-associated myelopathy or tropical spastic paraparesis patients as in asymptomatic carriers but at a lower level in adult T-cell leukemia cells. *Blood* 1995, 85:1865–1870
9. Gessain A, Louie A, Gout O, Gallo RC, Franchini G: Human T-cell leukemia-lymphoma virus type I (HTLV-I) expression in fresh peripheral blood mononuclear cells from patients with tropical spastic paraparesis/HTLV-I-associated myelopathy. *J Virol* 1991, 65:1628–1633
10. Nagai K, Jinnai I, Hata T, Usui T, Sasaki D, Tsukasaki K, Sugahara K, Hishikawa Y, Yamada Y, Tanaka Y, Koji T, Mano H, Kamihira S, Tomonaga M: Adhesion-dependent growth of primary adult T cell leukemia cells with down-regulation of HTLV-I p40Tax protein: a novel in vitro model of the growth of acute ATL cells. *Int J Hematol* 2008, 88:551–564
11. Kinpara S, Hasegawa A, Utsunomiya A, Nishitsuji H, Furukawa H, Masuda T, Kannagi M: Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. *J Virol* 2009, 83:5101–5108
12. Michael B, Nair AM, Datta A, Hiraragi H, Ratner L, Lairmore MD: Histone acetyltransferase (HAT) activity of p300 modulates human T lymphotropic virus type 1 p30II-mediated repression of LTR transcriptional activity. *Virology* 2006, 354:225–239
13. Ego T, Ariumi Y, Shimotohno K: The interaction of HTLV-1 Tax with HDAC1 negatively regulates the viral gene expression. *Oncogene* 2002, 21:7241–7246
14. Mosley AJ, Meekings KN, McCarthy C, Shepherd D, Cerundolo V, Mazitschek R, Tanaka Y, Taylor GP, Bangham CR: Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infection. *Blood* 2006, 108:3801–3807
15. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV: Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. *Br J Haematol* 1996, 92:97–103
16. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P: Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. *Blood* 1998, 91:2387–2396
17. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ: Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. *Blood* 2000, 96:2655–2663
18. Kawaguchi A, Orba Y, Kimura T, Iha H, Ogata M, Tsuji T, Ainai A, Sata T, Okamoto T, Hall WW, Sawa H, Hasegawa H: Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. *Blood* 2009, 114:2961–2968
19. Wayner EA, Gil SG, Murphy GF, Wilke MS, Carter WG: Epiligrin, a component of epithelial basement membranes, is an adhesive ligand for alpha 3 beta 1 positive T lymphocytes. *J Cell Biol* 1993, 121:1141–1152
20. Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, Fahim S, Keating A: KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. *Exp Hematol* 2005, 33:1160–1171
21. Sheehy N, Lillis L, Watters K, Lewis M, Gautier V, Hall WW: Functional analysis of human T lymphotropic virus type 2 Tax proteins. *Retrovirology* 2006, 3:20
22. Green KJ, Rowbottom DG: Exercise-induced changes to in vitro T-lymphocyte mitogen responses using CFSE. *J Appl Physiol* 2003, 95:57–63
23. Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 2012, 9:671–675
24. Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T: Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. *Cancer Res* 1999, 59:4266–4270
25. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008, 133:704–715
26. Ferrari S, Battini R, Kaczmarek L, Rittling S, Calabretta B, de Riel JK, Philiponis V, Wei JF, Baserga R: Coding sequence and growth regulation of the human vimentin gene. *Mol Cell Biol* 1986, 6:3614–3620
27. Su YJ, Lai HM, Chang YW, Chen GY, Lee JL: Direct reprogramming of stem cell properties in colon cancer cells by CD44. *EMBO J* 2011, 30:3186–3199
28. Lee JL, Wang MJ, Chen JY: Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. *J Cell Biol* 2009, 185:949–957
29. Gleimer M, Parham P: Stress management: MHC class I and class I like molecules as reporters of cellular stress. *Immunity* 2003, 19:469–477
30. Raulet DH, Guerra N: Oncogenic stress sensed by the immune system: role of natural killer cell receptors. *Nat Rev Immunol* 2009, 9:568–580
31. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress inducible MICA. *Science* 1999, 285:727–729
32. Marks PA, Richon VM, Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. *J Natl Cancer Inst* 2000, 92:1210–1216
33. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ: Histone deacetylases as regulators of inflammation and immunity. *Trends Immunol* 2011, 32:335–343
34. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C: Histone deacetylase inhibitors and genomic instability. *Cancer Lett* 2009, 274:169–176
35. Solis MA, Chen YH, Wong TY, Bittencourt VZ, Lin YC, Huang LL: Hyaluronan regulates cell behavior: a potential niche matrix for stem cells. *Biochem Res Int* 2012, 2012:346972
36. Chagan-Yasutan H, Tsukasaki K, Takahashi Y, Oguma S, Harigae H, Ishii N, Zhang J, Fukumoto M, Hattori T: Involvement of osteopontin and its signaling molecule CD44 in clinicopathological features of adult T cell leukemia. *Leuk Res* 2011, 35:1484–1490
37. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. *J Clin Oncol* 2007, 25:3109–3115
38. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE: Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. *Blood* 2011, 117:5827–5834
39. Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A, Kuwayama Y, Togitani K, Koeffler HP, Taguchi H: Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. *Leuk Res* 2008, 32:287–296
40. Hasegawa H, Yamada Y, Tsukasaki K, Mori N, Tsuruda K, Sasaki D, Usui T, Osaka A, Atogami S, Ishikawa C, Machijima Y, Sawada S, Hayashi T, Miyazaki Y, Kamihira S: LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. *Leukemia* 2011, 25:575–587

